Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy

Introduction: Rituximab is a first-line treatment for primary membranous nephropathy (pMN), with proven efficacy and safety. The use of monoclonal antibodies such as rituximab can lead to the formation of antidrug antibodies that may interfere with the therapeutic response. In pMN, anti-rituximab an...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Kidney International Reports
المؤلفون الرئيسيون:	Marco Allinovi, Maxime Teisseyre, Matteo Accinno, Cecilia Finocchi, Vincent L.M. Esnault, Marion Cremoni, Tommaso Mazzierli, Daniela Lazzarini, Micaela Anna Casiraghi, Céline Fernandez, Kévin Zorzi, Vesna Brglez, Lorenzo Cosmi, Andrea Matucci, Leonardo Caroti, Giulia Antognoli, Calogero Lino Cirami, Alessandra Vultaggio, Barbara Seitz-Polski
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2025-08-01
الموضوعات:	antidrug antibody anti-rituximab antibody immunogenicity membranous nephropathy neutralizing antibodies rituximab
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2468024925002840